Sandberg E, Costanzo A, Daas A, Buchheit K-H
Danish Medicines Agency, Copenhagen, Denmark.
Pharmeur Bio Sci Notes. 2012 Apr;2012:1-15.
The current European Pharmacopoeia (Ph. Eur.) Biological Reference Preparation batch 3 (BRP3) for Human Immunoglobulin was established in 2005. Stocks of this BRP are dwindling and a replacement batch is needed to serve as working standard in the tests for distribution of molecular size by HPLC, anticomplementary activity (ACA) and Fc function, in accordance with the requirements of the Ph. Eur. monographs Human normal immunoglobulin (0338) and Human normal immunoglobulin for intravenous administration (0918). The European Directorate for the Quality of Medicines & HealthCare (EDQM) carried out a project (BSP099) to establish replacement batches for this BRP. The project was run in 2 phases, a prequalification phase (Phase 1) and an international collaborative study (Phase 2) involving 19 laboratories. Three batches of candidate materials of various sizes, Samples A, B and C, were procured from 2 different manufacturers on the European market. Based on the results of the study, Sample A was shown to be suitable as a reference standard for the ACA test and for molecular size determination by HPLC, whereas Samples B and C were demonstrated to be suitable for the Fc function test and for the molecular size determination by HPLC. All 3 BRPs are to be used in conjunction with the monographs Human normal immunoglobulin (0338) and Human normal immunoglobulin for intravenous administration (0918). The BRPs were adopted by the Ph. Eur. Commission at its 141st session in November 2011 as official Ph. Eur. Human Immunoglobulin BRPs for ACA and molecular size Batch 1 (Sample A) and Fc function and molecular size Batch 1 and Batch 2 (Samples B and C respectively).
现行欧洲药典(Ph. Eur.)人免疫球蛋白生物参考制剂第3批(BRP3)于2005年建立。该BRP的库存正在减少,需要一批替代批次作为工作标准,以根据欧洲药典专论《人正常免疫球蛋白》(0338)和《静脉注射用人正常免疫球蛋白》(0918)的要求,进行高效液相色谱法(HPLC)分子大小分布测试、抗补体活性(ACA)测试和Fc功能测试。欧洲药品质量管理局(EDQM)开展了一个项目(BSP099)来建立该BRP的替代批次。该项目分两个阶段进行,一个是预认证阶段(第1阶段),另一个是涉及19个实验室的国际协作研究(第2阶段)。从欧洲市场的2家不同制造商采购了3批不同大小的候选材料,即样品A、B和C。根据研究结果,样品A被证明适合作为ACA测试和HPLC分子大小测定的参考标准,而样品B和C被证明适合Fc功能测试和HPLC分子大小测定。所有3种BRP均应与专论《人正常免疫球蛋白》(0338)和《静脉注射用人正常免疫球蛋白》(0918)结合使用。这些BRP在2011年11月举行的欧洲药典委员会第141届会议上被采用,作为欧洲药典官方人免疫球蛋白BRP,其中ACA和分子大小第1批(样品A),Fc功能和分子大小第1批和第2批(分别为样品B和C)。